12/11
07:22 am
crvs
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% [Yahoo! Finance]
Low
Report
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% [Yahoo! Finance]
12/4
04:14 pm
crvs
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity [Yahoo! Finance]
12/4
04:05 pm
crvs
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Low
Report
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
11/15
10:47 am
crvs
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Low
Report
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
11/14
10:14 am
crvs
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]
11/14
10:01 am
crvs
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Medium
Report
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
11/13
10:08 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.
11/13
02:26 am
crvs
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... [Yahoo! Finance]
11/13
12:04 am
crvs
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/12
04:12 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/12
04:01 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
11/9
01:40 pm
crvs
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Low
Report
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
11/6
05:13 am
crvs
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals [Yahoo! Finance]
Medium
Report
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals [Yahoo! Finance]
11/5
04:02 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Medium
Report
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
10/31
02:04 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/24
07:25 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
10/23
11:07 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/22
11:52 am
crvs
Corvus stock climbs 7% following Mizuho upgrade [Seeking Alpha]
Neutral
Report
Corvus stock climbs 7% following Mizuho upgrade [Seeking Alpha]
10/17
09:12 am
crvs
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment [Yahoo! Finance]
Low
Report
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment [Yahoo! Finance]
10/11
02:08 am
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
9/27
11:07 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.